Anti-citrullinated procollagen C-endopeptidase enhancer antibody (anti-PCOLCE): a potential biomarker for seronegative rheumatoid arthritis
Authors' conclusion
Anti-PCOLCE could serve as a novel biomarker for RA, especially for seronegative RA.
Study context
- Population
- Serum samples from rheumatoid arthritis (RA) patients, healthy controls and patients with other rheumatic diseases
- Participants
- 612 serum samples
- Comparison
- Anti-citrullinated PCOLCE271-284 antibody (anti-PCOLCE), alone and combined with anti-CCP, for RA diagnosis
- Outcome
- Diagnostic value of anti-PCOLCE in RA, especially seronegative RA (ROC curve, sensitivity, specificity)
Methodological detailsB-cell epitope prediction (Immune Epitope Database and molecular mimicry analyses), ROC curve analysis
- B-cell epitope prediction (Immune Epitope Database and molecular mimicry analyses)
- ROC curve analysis
Performance
As reported in the abstract
Diagnostic performance for RA
| Test or model | Sensitivity | Specificity |
|---|---|---|
| Anti-PCOLCE | 51.53% | 93.60% |
Anti-PCOLCE
Sensitivity51.53%
Specificity93.60%
Further findings
| Outcome | Anti-PCOLCE + anti-CCP |
|---|---|
| Diagnostic performance of anti-PCOLCE combined with anti-CCP for RA | |
| Sensitivity | 82.14% |
| Specificity | 90.21% |
Anti-PCOLCE positive rate in seronegative RA
- Anti-CCP negative RA
- 40.00%
- RF negative RA
- 38.76%
- Anti-CCP and RF negative RA
- 36.46%
Anti-PCOLCE in RA with normal inflammatory factors and early RA
- Good diagnostic value
Correlations of anti-PCOLCE with RA patient features
- Positively correlated with CRP, anti-CCP and RF
Original publication
Anti-citrullinated procollagen C-endopeptidase enhancer antibody (anti-PCOLCE): a potential biomarker for seronegative rheumatoid arthritis. Rheumatology (Oxford). Published 5 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →